Experimental vaccine aims to stop liver cancer from returning
NCT ID NCT06218511
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a cancer vaccine (IMA970A) combined with an immunotherapy drug (durvalumab) in 10 patients with early- to intermediate-stage liver cancer who have already received standard treatments. The goal is to see if the combination is safe and can help reduce the risk of the cancer coming back. Participants will receive the vaccine and drug without other anti-cancer therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a peptide vaccine (IMA970A) combined with an immune checkpoint inhibitor (durvalumab) and an adjuvant (Montanide)
What this could lead to
If successful, this could point toward a new way to lower the chance of liver cancer coming back after standard treatments.
What could go wrong
This is a very early, small phase I trial with only 10 participants, so it is mainly testing safety. The vaccine may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Luigi Buonaguro
Naples, Napoli, 80131, Italy